Analysis in the TCGA-LIHC dataset revealed that HCC with low LRRC59 expression were associated with sensitivity to TACE treatment (Supplementary Figure 7C), and insensitivity to Sorafenib treatment (Supplementary Figure 7D). This evidence concerns the gene LRRC59 and hepatocellular carcinoma.